Journal Article

Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin.

Y Vanrenterghem and J Vanwalleghem

in Nephrology Dialysis Transplantation

Volume 13, issue suppl_2, pages 13-15
Published in print January 1998 | ISSN: 0931-0509
Published online January 1998 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/13.suppl_2.13
Benefits and concerns of treating pre-dialysis and renal transplant patients with recombinant human erythropoietin.

Show Summary Details

Preview

The possibility of lower efficacy and the fear of an increased incidence of side effects may explain the reluctance to use recombinant human erythropoietin (r-HuEPO) in patients with impaired renal function who do not yet require dialysis, as well as in transplanted patients with a failing renal allograft. Several recent studies have clearly shown that r-HuEPO is effective in these patient populations and that the doses needed to control anaemia are comparable with or lower than those needed for dialysis patients. When started at a low dose, the risk of severe hypertension is minimal, although in a significant number of patients intensification of the antihypertensive regimen is needed. Moreover, there are no indications that the use of r-HuEPO accelerates the deterioration of residual renal function.

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.